<DOC>
	<DOCNO>NCT01803724</DOCNO>
	<brief_summary>The Irritable Bowel Syndrome ( IBS ) frequent disease , affect 10 20 % general population . Several pathophysiologic mechanism describe IBS , among role intestinal microbiota small intestinal bacterial overgrowth ( SIBO ) receive special attention . SIBO adequate response antibiotic treatment , unfortunately n't adequate diagnostic test : The classic gold standard -jejunal aspirate culture- criticize due lack standardization ; breath test simpler widely available , also criticize due inadequate diagnostic accuracy SIBO . For reason seem important evaluate performance breath test term predict clinical benefit antibiotic therapy IBS patient , rather predict positive culture SIBO . The objective study : 1 . Determine breath test ( lactulose glucose ) predict well potential clinical benefit antibiotic treatment ( Rifaximin ) IBS patient . 2 . Determine multiple diagnostic criterion describe lactulose breath test predict well potential clinical benefit Rifaximin IBS patient .</brief_summary>
	<brief_title>Lactulose Glucose Breath Tests Predictors Clinical Benefit From Rifaximin Irritable Bowel Syndrome</brief_title>
	<detailed_description>After sign informed consent , patient submit glucose lactulose breath test within 10 day period . The order test randomize use random number list allocation , know patient . For lactulose test 10 g glucose test 50 g dose use , previously suggest . After second test , patient receive Rifaximin 400 mg TID ( 1200 mg/day ) 10 day . In case methane producer ( define patient basal methane level &gt; 3 ppm ) Neomycin 500 mg BID ( 1000 mg/day ) ten day add , suggest Low et al . Two week antibiotic course , patient cite follow data assess : 1 . Adequate relief global IBS symptom . 2 . Adequate relief bloating . 3 . Evaluation IBS severity use IBSSS . 4 . Drug induce side effect . Only information submit patient , result test reveal . Patients classify responder accord global symptom adequate relief status . Using gold standard criterion , test performance , term sensitivity , specificity , positive negative predictive value , calculate follow test : 1 . Glucose breath test . A ROC curve calculate determine best cutoff value 2 . Lactulose breath test use rise occur 60 min , without presence double peak . A ROC curve calculate determine best cutoff value 3 . Lactulose breath test use rise occur 60 min , double peak . A ROC curve calculate determine best cutoff value 4 . Lactulose breath test use rise occur 90 min , without presence double peak . A ROC curve calculate determine best cutoff value 5 . Lactulose breath test use rise occur 90 min , double peak . A ROC curve calculate determine best cutoff value The different test compare term performance optimal cutoff value calculate area ROC curve . The sample size calculate previously suggest . Using Shah et al data , assume sensitivity 72 % specificity 66 % lactulose breath test . Using alpha beta error 5 % 20 % , respectively , disease prevalence 35 % ( SIBO IBS ) , estimate sample size 120 patient .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<criteria>Patients meet Rome III criterion IBS . 1 . Patients &lt; 18 year old 2 . Previous intestinal ( small large bowel ) resection 3 . Known anatomical intestinal alteration , include diverticula stenosis 4 . Inflamatory bowel disease ( Crohn´s ulcerative colitis ) 5 . Presence IBS alarm sign suggestive organic disease , include anemia family history celiac disease colon cancer 6 . Recent acute onset diarrhea 7 . Pregnancy 8 . Neurologic psychiatric disease may allow patient appropriately describe clinical outcome 9 . Presence disease could affect intestinal transit , Parkinson´s , Chronic Intestinal Pseudobstruction , Scleroderma , Diabetes mellitus , etc 10 . Impossibility transitory withdraw drug affect intestinal transit , Calcium channel blocker , tricyclic 11 . Inability sign rejection inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Irritable Bowel Syndrome</keyword>
	<keyword>Small Intestinal Bacterial Overgrowth</keyword>
	<keyword>Lactulose breath test</keyword>
	<keyword>Glucose breath test</keyword>
	<keyword>Rifaximin</keyword>
</DOC>